OSE Pharma merge with Effimune to create OSE Immunotherapeutics

1 June 2016


OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics

Paris, Nantes, May 31, 2016 – OSE Pharma SA (ISIN : FR0012127173 ; Mémo : OSE), an immuno-oncology company developing a T-specific immunotherapy, currently in a registration Phase 3 study, is pleased to announce the approval of resolutions submitted to shareholders during the Combined General Shareholders’ Meeting of May 31, 2016, including approval of the merger with Effimune, a biotechnology company specializing in immune regulation.

OSE Immunotherapeutics, the new entity resulting from the merger, will develop innovative treatments aiming at activating or regulating the immune system to restore immune disorders in immuno-oncology, autoimmune diseases and transplantation.


To read the complete release